Life Sciences
R&D/ Views & Analysis/ Views and analysis
How Design of Experiments enriches life sciences’ findings
mike.hammerton@pharmaphorum.com
biological systems, Design of Experiments, High Dimensional Experimentation, Life Sciences, methodology
0 Comment
Digital/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
The importance of AI literacy in life sciences
mike.hammerton@pharmaphorum.com
AI, Biotech, Education, law of increasing return, Life Sciences, pharma, strategy, technology
0 Comment
R&D/ Views & Analysis/ Views and analysis
Connected customer data: a golden opportunity for pharma marketers
mike.hammerton@pharmaphorum.com
customer data, customer experience, data access, Life Sciences, new technologies, pharma marketing
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis
Another inside peek into pharma marketing at PM Society learning event
Nicole Raleigh
development, leadership, learning, Life Sciences, pharma, PM Society, strategy, The Red Thread
0 Comment
Market Access/ Sustainability/ Transversal Categories/ Views & Analysis/ Views and analysis
Life sciences faces a battle with sustainability, but let’s not forget its successes
mike.hammerton@pharmaphorum.com
carbon emissions, COP27, global healthcare, Life Sciences, net zero, Sustainability
0 Comment
Digital/ R&D/ Views and analysis
New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation
mike.smith@pharmaphorum.com
Angelini Ventures, digital health, Life Sciences
0 Comment
News/ News/ Sales and Marketing
GSK to move HQ to central London, as Canary Wharf plans filed
Phil Taylor
Biotech, Canary Wharf Group, cluster, GSK, investment, Life Sciences, UK
0 Comment
R&D/ Views & Analysis/ Views and analysis
How eligible patient numbers affect price of rare disease drugs in France
mike.hammerton@pharmaphorum.com
CRA, Drug pricing, France, Life Sciences, patient numbers, rare disease
0 Comment